Dr. Lachowiez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-5058Fax+1 503-494-5065
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
University of Nebraska College of MedicineClass of 2015
Certifications & Licensure
OR State Medical License 2017 - 2025
TX State Medical License 2020 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- 2 citationsClinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System.Effrosyni Apostolidou, Curtis Lachowiez, Harinder S. Juneja, Wei Qiao, Onyebuchi Ononogbu
Clinical Lymphoma, Myeloma & Leukemia. 2020-09-01 - 27 citationsTargeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.Courtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi
Blood Advances. 2023-06-13 - 30 citationsComparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Curtis A Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F Newell
Blood Advances. 2023-05-09
Press Mentions
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024October 24th, 2024- ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid LeukemiaSeptember 9th, 2024
- Determining the Optimal Frontline Treatment of AMLDecember 6th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
